nodes	percent_of_prediction	percent_of_DWPC	metapath
Bismuth Subsalicylate—PTGS2—thyroid cancer	0.755	1	CbGaD
Bismuth Subsalicylate—ALB—Vandetanib—thyroid cancer	0.0772	1	CbGbCtD
Bismuth Subsalicylate—PTGS1—Eicosanoid Synthesis—PTGES2—thyroid cancer	0.00779	0.0851	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Eicosanoid Synthesis—PTGES2—thyroid cancer	0.00619	0.0675	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGD—thyroid cancer	0.00586	0.0639	CbGpPWpGaD
Bismuth Subsalicylate—TF—Iron uptake and transport—CP—thyroid cancer	0.00483	0.0528	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGD—thyroid cancer	0.00465	0.0508	CbGpPWpGaD
Bismuth Subsalicylate—TF—Differentiation Pathway—EPO—thyroid cancer	0.00347	0.0379	CbGpPWpGaD
Bismuth Subsalicylate—TF—HIF-1-alpha transcription factor network—CP—thyroid cancer	0.00343	0.0374	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Prostaglandin Synthesis and Regulation—HPGD—thyroid cancer	0.00318	0.0348	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Signaling mediated by p38-alpha and p38-beta—KRT19—thyroid cancer	0.00277	0.0303	CbGpPWpGaD
Bismuth Subsalicylate—TF—SIDS Susceptibility Pathways—RET—thyroid cancer	0.00274	0.03	CbGpPWpGaD
Bismuth Subsalicylate—TF—HIF-1-alpha transcription factor network—EPO—thyroid cancer	0.00269	0.0294	CbGpPWpGaD
Bismuth Subsalicylate—TF—SIDS Susceptibility Pathways—THRB—thyroid cancer	0.00255	0.0279	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Prostaglandin Synthesis and Regulation—HPGD—thyroid cancer	0.00253	0.0276	CbGpPWpGaD
Bismuth Subsalicylate—Lethargy—Vandetanib—thyroid cancer	0.00222	0.0292	CcSEcCtD
Bismuth Subsalicylate—Hyponatraemia—Vandetanib—thyroid cancer	0.00218	0.0287	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Arachidonic acid metabolism—HPGD—thyroid cancer	0.00212	0.0231	CbGpPWpGaD
Bismuth Subsalicylate—Skin exfoliation—Sorafenib—thyroid cancer	0.00193	0.0254	CcSEcCtD
Bismuth Subsalicylate—TF—SIDS Susceptibility Pathways—PRKAR1A—thyroid cancer	0.0017	0.0185	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Arachidonic acid metabolism—HPGD—thyroid cancer	0.00168	0.0183	CbGpPWpGaD
Bismuth Subsalicylate—TF—HIF-1-alpha transcription factor network—TERT—thyroid cancer	0.00168	0.0183	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—RET—thyroid cancer	0.00164	0.0179	CbGpPWpGaD
Bismuth Subsalicylate—TF—HIF-1-alpha transcription factor network—HIF1A—thyroid cancer	0.0016	0.0175	CbGpPWpGaD
Bismuth Subsalicylate—Epistaxis—Vandetanib—thyroid cancer	0.00158	0.0208	CcSEcCtD
Bismuth Subsalicylate—Hyponatraemia—Sorafenib—thyroid cancer	0.00147	0.0194	CcSEcCtD
Bismuth Subsalicylate—Erythema multiforme—Vandetanib—thyroid cancer	0.00142	0.0187	CcSEcCtD
Bismuth Subsalicylate—Venous thrombosis—Epirubicin—thyroid cancer	0.00138	0.0182	CcSEcCtD
Bismuth Subsalicylate—ALB—FOXA2 and FOXA3 transcription factor networks—NKX2-1—thyroid cancer	0.00134	0.0146	CbGpPWpGaD
Bismuth Subsalicylate—TF—SIDS Susceptibility Pathways—SST—thyroid cancer	0.00134	0.0146	CbGpPWpGaD
Bismuth Subsalicylate—Abdominal pain upper—Sorafenib—thyroid cancer	0.00134	0.0176	CcSEcCtD
Bismuth Subsalicylate—Gastric ulcer—Epirubicin—thyroid cancer	0.00128	0.0169	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Vandetanib—thyroid cancer	0.00128	0.0169	CcSEcCtD
Bismuth Subsalicylate—Venous thrombosis—Doxorubicin—thyroid cancer	0.00128	0.0168	CcSEcCtD
Bismuth Subsalicylate—TF—EPHB forward signaling—NRAS—thyroid cancer	0.00127	0.0139	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Recycling of bile acids and salts—RXRA—thyroid cancer	0.00122	0.0133	CbGpPWpGaD
Bismuth Subsalicylate—Abdominal discomfort—Sorafenib—thyroid cancer	0.00121	0.016	CcSEcCtD
Bismuth Subsalicylate—Gastric ulcer—Doxorubicin—thyroid cancer	0.00119	0.0156	CcSEcCtD
Bismuth Subsalicylate—TF—EPHB forward signaling—KRAS—thyroid cancer	0.00109	0.0119	CbGpPWpGaD
Bismuth Subsalicylate—Burning sensation—Epirubicin—thyroid cancer	0.00107	0.0141	CcSEcCtD
Bismuth Subsalicylate—Oedema—Vandetanib—thyroid cancer	0.00107	0.0141	CcSEcCtD
Bismuth Subsalicylate—Epistaxis—Sorafenib—thyroid cancer	0.00106	0.014	CcSEcCtD
Bismuth Subsalicylate—Infection—Vandetanib—thyroid cancer	0.00106	0.014	CcSEcCtD
Bismuth Subsalicylate—Lung disorder—Epirubicin—thyroid cancer	0.00105	0.0139	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—thyroid cancer	0.00105	0.0115	CbGpPWpGaD
Bismuth Subsalicylate—Burning sensation—Doxorubicin—thyroid cancer	0.000993	0.0131	CcSEcCtD
Bismuth Subsalicylate—Lung disorder—Doxorubicin—thyroid cancer	0.000975	0.0128	CcSEcCtD
Bismuth Subsalicylate—Erythema multiforme—Sorafenib—thyroid cancer	0.000958	0.0126	CcSEcCtD
Bismuth Subsalicylate—Tinnitus—Sorafenib—thyroid cancer	0.000945	0.0124	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Vandetanib—thyroid cancer	0.00094	0.0124	CcSEcCtD
Bismuth Subsalicylate—TF—EPHB forward signaling—HRAS—thyroid cancer	0.000929	0.0101	CbGpPWpGaD
Bismuth Subsalicylate—Decreased appetite—Vandetanib—thyroid cancer	0.000928	0.0122	CcSEcCtD
Bismuth Subsalicylate—Stinging—Epirubicin—thyroid cancer	0.000921	0.0121	CcSEcCtD
Bismuth Subsalicylate—Constipation—Vandetanib—thyroid cancer	0.000913	0.012	CcSEcCtD
Bismuth Subsalicylate—Pain—Vandetanib—thyroid cancer	0.000913	0.012	CcSEcCtD
Bismuth Subsalicylate—Erythema—Sorafenib—thyroid cancer	0.000882	0.0116	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Sorafenib—thyroid cancer	0.000864	0.0114	CcSEcCtD
Bismuth Subsalicylate—Extravasation—Epirubicin—thyroid cancer	0.000855	0.0113	CcSEcCtD
Bismuth Subsalicylate—Stinging—Doxorubicin—thyroid cancer	0.000852	0.0112	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Vandetanib—thyroid cancer	0.000844	0.0111	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Overview of nanoparticle effects—PTGS2—thyroid cancer	0.000823	0.00899	CbGpPWpGaD
Bismuth Subsalicylate—TF—SIDS Susceptibility Pathways—HIF1A—thyroid cancer	0.000805	0.00879	CbGpPWpGaD
Bismuth Subsalicylate—Extravasation—Doxorubicin—thyroid cancer	0.000791	0.0104	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Vandetanib—thyroid cancer	0.000755	0.00995	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Vandetanib—thyroid cancer	0.00073	0.00962	CcSEcCtD
Bismuth Subsalicylate—Infection—Sorafenib—thyroid cancer	0.000715	0.00942	CcSEcCtD
Bismuth Subsalicylate—Skin exfoliation—Epirubicin—thyroid cancer	0.000712	0.00938	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Vandetanib—thyroid cancer	0.000706	0.0093	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Sorafenib—thyroid cancer	0.000686	0.00904	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Eicosanoid Synthesis—PTGS2—thyroid cancer	0.000683	0.00745	CbGpPWpGaD
Bismuth Subsalicylate—Oesophagitis—Epirubicin—thyroid cancer	0.000682	0.00898	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Vandetanib—thyroid cancer	0.000679	0.00894	CcSEcCtD
Bismuth Subsalicylate—Ecchymosis—Epirubicin—thyroid cancer	0.000674	0.00888	CcSEcCtD
Bismuth Subsalicylate—Rash—Vandetanib—thyroid cancer	0.000673	0.00887	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Vandetanib—thyroid cancer	0.000672	0.00886	CcSEcCtD
Bismuth Subsalicylate—Headache—Vandetanib—thyroid cancer	0.000669	0.00881	CcSEcCtD
Bismuth Subsalicylate—TF—Hemostasis—PRKAR1A—thyroid cancer	0.000662	0.00722	CbGpPWpGaD
Bismuth Subsalicylate—Skin exfoliation—Doxorubicin—thyroid cancer	0.000659	0.00868	CcSEcCtD
Bismuth Subsalicylate—ALB—Bile acid and bile salt metabolism—RXRA—thyroid cancer	0.000638	0.00697	CbGpPWpGaD
Bismuth Subsalicylate—Nausea—Vandetanib—thyroid cancer	0.000634	0.00835	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Sorafenib—thyroid cancer	0.000634	0.00835	CcSEcCtD
Bismuth Subsalicylate—Oesophagitis—Doxorubicin—thyroid cancer	0.000631	0.00831	CcSEcCtD
Bismuth Subsalicylate—Phlebitis—Epirubicin—thyroid cancer	0.000629	0.00828	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Sorafenib—thyroid cancer	0.000626	0.00824	CcSEcCtD
Bismuth Subsalicylate—Ecchymosis—Doxorubicin—thyroid cancer	0.000624	0.00822	CcSEcCtD
Bismuth Subsalicylate—Pain—Sorafenib—thyroid cancer	0.000616	0.00811	CcSEcCtD
Bismuth Subsalicylate—Constipation—Sorafenib—thyroid cancer	0.000616	0.00811	CcSEcCtD
Bismuth Subsalicylate—TF—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000582	0.00635	CbGpPWpGaD
Bismuth Subsalicylate—TF—Transmembrane transport of small molecules—CP—thyroid cancer	0.000582	0.00635	CbGpPWpGaD
Bismuth Subsalicylate—Phlebitis—Doxorubicin—thyroid cancer	0.000582	0.00766	CcSEcCtD
Bismuth Subsalicylate—TF—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000573	0.00625	CbGpPWpGaD
Bismuth Subsalicylate—Urticaria—Sorafenib—thyroid cancer	0.000572	0.00753	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—thyroid cancer	0.000571	0.00624	CbGpPWpGaD
Bismuth Subsalicylate—Body temperature increased—Sorafenib—thyroid cancer	0.000569	0.0075	CcSEcCtD
Bismuth Subsalicylate—Lethargy—Epirubicin—thyroid cancer	0.000553	0.00728	CcSEcCtD
Bismuth Subsalicylate—Hyponatraemia—Epirubicin—thyroid cancer	0.000544	0.00716	CcSEcCtD
Bismuth Subsalicylate—TF—HIF-1-alpha transcription factor network—AKT1—thyroid cancer	0.000539	0.00588	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000535	0.00585	CbGpPWpGaD
Bismuth Subsalicylate—Lethargy—Doxorubicin—thyroid cancer	0.000511	0.00673	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Sorafenib—thyroid cancer	0.000509	0.00671	CcSEcCtD
Bismuth Subsalicylate—Hyponatraemia—Doxorubicin—thyroid cancer	0.000503	0.00663	CcSEcCtD
Bismuth Subsalicylate—Abdominal pain upper—Epirubicin—thyroid cancer	0.000495	0.00651	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Sorafenib—thyroid cancer	0.000493	0.00649	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—LGALS3—thyroid cancer	0.000481	0.00525	CbGpPWpGaD
Bismuth Subsalicylate—Dizziness—Sorafenib—thyroid cancer	0.000476	0.00627	CcSEcCtD
Bismuth Subsalicylate—Asthma—Epirubicin—thyroid cancer	0.000468	0.00616	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Sorafenib—thyroid cancer	0.000458	0.00603	CcSEcCtD
Bismuth Subsalicylate—Abdominal pain upper—Doxorubicin—thyroid cancer	0.000458	0.00603	CcSEcCtD
Bismuth Subsalicylate—Rash—Sorafenib—thyroid cancer	0.000454	0.00598	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Sorafenib—thyroid cancer	0.000454	0.00597	CcSEcCtD
Bismuth Subsalicylate—Headache—Sorafenib—thyroid cancer	0.000451	0.00594	CcSEcCtD
Bismuth Subsalicylate—TF—Hemostasis—IFNA2—thyroid cancer	0.000438	0.00478	CbGpPWpGaD
Bismuth Subsalicylate—TF—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000436	0.00476	CbGpPWpGaD
Bismuth Subsalicylate—Asthma—Doxorubicin—thyroid cancer	0.000433	0.0057	CcSEcCtD
Bismuth Subsalicylate—Nausea—Sorafenib—thyroid cancer	0.000428	0.00563	CcSEcCtD
Bismuth Subsalicylate—Weight increased—Epirubicin—thyroid cancer	0.000426	0.00561	CcSEcCtD
Bismuth Subsalicylate—Drowsiness—Epirubicin—thyroid cancer	0.000417	0.0055	CcSEcCtD
Bismuth Subsalicylate—Weight increased—Doxorubicin—thyroid cancer	0.000394	0.00519	CcSEcCtD
Bismuth Subsalicylate—Epistaxis—Epirubicin—thyroid cancer	0.000394	0.00518	CcSEcCtD
Bismuth Subsalicylate—Drowsiness—Doxorubicin—thyroid cancer	0.000386	0.00509	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—thyroid cancer	0.000383	0.00418	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.00038	0.00414	CbGpPWpGaD
Bismuth Subsalicylate—Hepatitis—Epirubicin—thyroid cancer	0.000375	0.00493	CcSEcCtD
Bismuth Subsalicylate—TF—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000366	0.004	CbGpPWpGaD
Bismuth Subsalicylate—Epistaxis—Doxorubicin—thyroid cancer	0.000364	0.0048	CcSEcCtD
Bismuth Subsalicylate—Erythema multiforme—Epirubicin—thyroid cancer	0.000354	0.00466	CcSEcCtD
Bismuth Subsalicylate—Tinnitus—Epirubicin—thyroid cancer	0.000349	0.0046	CcSEcCtD
Bismuth Subsalicylate—Hepatitis—Doxorubicin—thyroid cancer	0.000347	0.00457	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—CDK1—thyroid cancer	0.000329	0.00359	CbGpPWpGaD
Bismuth Subsalicylate—Erythema multiforme—Doxorubicin—thyroid cancer	0.000328	0.00432	CcSEcCtD
Bismuth Subsalicylate—Erythema—Epirubicin—thyroid cancer	0.000326	0.00429	CcSEcCtD
Bismuth Subsalicylate—Tinnitus—Doxorubicin—thyroid cancer	0.000323	0.00426	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Epirubicin—thyroid cancer	0.000319	0.00421	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000302	0.0033	CbGpPWpGaD
Bismuth Subsalicylate—Erythema—Doxorubicin—thyroid cancer	0.000302	0.00397	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Doxorubicin—thyroid cancer	0.000295	0.00389	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Biological oxidations—RXRA—thyroid cancer	0.000284	0.00311	CbGpPWpGaD
Bismuth Subsalicylate—Confusional state—Epirubicin—thyroid cancer	0.000268	0.00353	CcSEcCtD
Bismuth Subsalicylate—Oedema—Epirubicin—thyroid cancer	0.000266	0.00351	CcSEcCtD
Bismuth Subsalicylate—Infection—Epirubicin—thyroid cancer	0.000264	0.00348	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Epirubicin—thyroid cancer	0.000254	0.00334	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—NRAS—thyroid cancer	0.000251	0.00274	CbGpPWpGaD
Bismuth Subsalicylate—Confusional state—Doxorubicin—thyroid cancer	0.000248	0.00327	CcSEcCtD
Bismuth Subsalicylate—Oedema—Doxorubicin—thyroid cancer	0.000246	0.00324	CcSEcCtD
Bismuth Subsalicylate—Infection—Doxorubicin—thyroid cancer	0.000245	0.00322	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Selenium Micronutrient Network—PTGS2—thyroid cancer	0.000241	0.00264	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.00024	0.00262	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—thyroid cancer	0.000239	0.0026	CbGpPWpGaD
Bismuth Subsalicylate—Somnolence—Epirubicin—thyroid cancer	0.000237	0.00312	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Doxorubicin—thyroid cancer	0.000235	0.00309	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Epirubicin—thyroid cancer	0.000234	0.00309	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Epirubicin—thyroid cancer	0.000231	0.00305	CcSEcCtD
Bismuth Subsalicylate—Pain—Epirubicin—thyroid cancer	0.000228	0.003	CcSEcCtD
Bismuth Subsalicylate—Constipation—Epirubicin—thyroid cancer	0.000228	0.003	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Epirubicin—thyroid cancer	0.000219	0.00289	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Doxorubicin—thyroid cancer	0.000219	0.00288	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Doxorubicin—thyroid cancer	0.000217	0.00285	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—KRAS—thyroid cancer	0.000216	0.00235	CbGpPWpGaD
Bismuth Subsalicylate—Decreased appetite—Doxorubicin—thyroid cancer	0.000214	0.00282	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Epirubicin—thyroid cancer	0.000211	0.00278	CcSEcCtD
Bismuth Subsalicylate—Pain—Doxorubicin—thyroid cancer	0.000211	0.00277	CcSEcCtD
Bismuth Subsalicylate—Constipation—Doxorubicin—thyroid cancer	0.000211	0.00277	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Epirubicin—thyroid cancer	0.00021	0.00277	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Metabolism—MINPP1—thyroid cancer	0.000209	0.00228	CbGpPWpGaD
Bismuth Subsalicylate—ALB—SLC-mediated transmembrane transport—CP—thyroid cancer	0.000209	0.00228	CbGpPWpGaD
Bismuth Subsalicylate—ALB—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.000209	0.00228	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	0.000208	0.00227	CbGpPWpGaD
Bismuth Subsalicylate—TF—Platelet activation, signaling and aggregation—AKT1—thyroid cancer	0.000205	0.00224	CbGpPWpGaD
Bismuth Subsalicylate—Feeling abnormal—Doxorubicin—thyroid cancer	0.000203	0.00267	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Doxorubicin—thyroid cancer	0.000196	0.00258	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Doxorubicin—thyroid cancer	0.000195	0.00256	CcSEcCtD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000194	0.00212	CbGpPWpGaD
Bismuth Subsalicylate—Pruritus—Epirubicin—thyroid cancer	0.000188	0.00248	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	0.000183	0.002	CbGpPWpGaD
Bismuth Subsalicylate—Diarrhoea—Epirubicin—thyroid cancer	0.000182	0.0024	CcSEcCtD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—CCND1—thyroid cancer	0.00018	0.00196	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—NDUFA13—thyroid cancer	0.000178	0.00194	CbGpPWpGaD
Bismuth Subsalicylate—Dizziness—Epirubicin—thyroid cancer	0.000176	0.00232	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Doxorubicin—thyroid cancer	0.000174	0.00229	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Epirubicin—thyroid cancer	0.000169	0.00223	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Doxorubicin—thyroid cancer	0.000168	0.00222	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Disease—TRIM24—thyroid cancer	0.000168	0.00184	CbGpPWpGaD
Bismuth Subsalicylate—Rash—Epirubicin—thyroid cancer	0.000168	0.00221	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Epirubicin—thyroid cancer	0.000168	0.00221	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Metabolism—CHST14—thyroid cancer	0.000167	0.00182	CbGpPWpGaD
Bismuth Subsalicylate—Headache—Epirubicin—thyroid cancer	0.000167	0.0022	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Metabolism—MINPP1—thyroid cancer	0.000166	0.00181	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—NRAS—thyroid cancer	0.000163	0.00178	CbGpPWpGaD
Bismuth Subsalicylate—Dizziness—Doxorubicin—thyroid cancer	0.000163	0.00214	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Disease—CHST14—thyroid cancer	0.000158	0.00173	CbGpPWpGaD
Bismuth Subsalicylate—Nausea—Epirubicin—thyroid cancer	0.000158	0.00208	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Doxorubicin—thyroid cancer	0.000157	0.00206	CcSEcCtD
Bismuth Subsalicylate—ALB—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.000156	0.00171	CbGpPWpGaD
Bismuth Subsalicylate—Rash—Doxorubicin—thyroid cancer	0.000155	0.00204	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Doxorubicin—thyroid cancer	0.000155	0.00204	CcSEcCtD
Bismuth Subsalicylate—ALB—Selenium Micronutrient Network—PTGS2—thyroid cancer	0.000155	0.00169	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—NRAS—thyroid cancer	0.000155	0.00169	CbGpPWpGaD
Bismuth Subsalicylate—Headache—Doxorubicin—thyroid cancer	0.000154	0.00203	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Disease—TRIM33—thyroid cancer	0.00015	0.00164	CbGpPWpGaD
Bismuth Subsalicylate—Nausea—Doxorubicin—thyroid cancer	0.000146	0.00193	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Metabolism—NDUFA13—thyroid cancer	0.000141	0.00154	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—KRAS—thyroid cancer	0.000141	0.00154	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—CCND1—thyroid cancer	0.000137	0.0015	CbGpPWpGaD
Bismuth Subsalicylate—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—thyroid cancer	0.000136	0.00148	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—HPGD—thyroid cancer	0.000135	0.00147	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—MINPP1—thyroid cancer	0.000134	0.00147	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—KRAS—thyroid cancer	0.000133	0.00145	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—CHST14—thyroid cancer	0.000133	0.00145	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—TP53—thyroid cancer	0.000125	0.00136	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—PRKAR1A—thyroid cancer	0.000121	0.00132	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—HRAS—thyroid cancer	0.00012	0.00131	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Folate Metabolism—TP53—thyroid cancer	0.000116	0.00127	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—NDUFA13—thyroid cancer	0.000114	0.00125	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—HRAS—thyroid cancer	0.000113	0.00124	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000109	0.00119	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—CHST14—thyroid cancer	0.000107	0.00117	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—HPGD—thyroid cancer	0.000107	0.00117	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—CP—thyroid cancer	0.000106	0.00116	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000106	0.00116	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—AKT1—thyroid cancer	0.000106	0.00115	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000104	0.00114	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—TCF7L1—thyroid cancer	0.0001	0.00109	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	9.32e-05	0.00102	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—TP53—thyroid cancer	9.02e-05	0.000985	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	8.99e-05	0.000982	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	8.67e-05	0.000947	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—HPGD—thyroid cancer	8.65e-05	0.000944	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—IFNA2—thyroid cancer	7.98e-05	0.000872	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	7.94e-05	0.000867	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—TPR—thyroid cancer	7.73e-05	0.000844	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PRKAR1A—thyroid cancer	7.61e-05	0.000831	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—TPR—thyroid cancer	7.33e-05	0.0008	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PRKAR1A—thyroid cancer	7.21e-05	0.000787	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	7.01e-05	0.000766	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	6.91e-05	0.000754	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	6.9e-05	0.000753	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—MEN1—thyroid cancer	6.89e-05	0.000752	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—RXRA—thyroid cancer	6.67e-05	0.000728	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—TPR—thyroid cancer	6.14e-05	0.00067	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	6.14e-05	0.00067	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PRKAR1A—thyroid cancer	6.04e-05	0.000659	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—SLC5A5—thyroid cancer	5.79e-05	0.000632	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CALCA—thyroid cancer	5.49e-05	0.000599	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	5.47e-05	0.000598	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	5.42e-05	0.000592	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	5.18e-05	0.000566	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CDK1—thyroid cancer	4.97e-05	0.000542	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—TPR—thyroid cancer	4.97e-05	0.000542	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PRKAR1A—thyroid cancer	4.89e-05	0.000533	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—RXRA—thyroid cancer	4.86e-05	0.000531	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	4.73e-05	0.000516	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—SLC5A5—thyroid cancer	4.6e-05	0.000502	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	4.43e-05	0.000484	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—NRG1—thyroid cancer	3.99e-05	0.000435	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—RXRA—thyroid cancer	3.86e-05	0.000422	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	3.76e-05	0.00041	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—AKT1—thyroid cancer	3.73e-05	0.000407	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—SLC5A5—thyroid cancer	3.72e-05	0.000406	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—TERT—thyroid cancer	3.58e-05	0.000391	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	3.48e-05	0.00038	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—HIF1A—thyroid cancer	3.42e-05	0.000374	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—RXRA—thyroid cancer	3.12e-05	0.000341	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PPARG—thyroid cancer	3.07e-05	0.000335	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	3.04e-05	0.000332	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—NRAS—thyroid cancer	2.98e-05	0.000325	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—BRAF—thyroid cancer	2.84e-05	0.00031	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—KRAS—thyroid cancer	2.56e-05	0.00028	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PPARG—thyroid cancer	2.44e-05	0.000266	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PTGS2—thyroid cancer	2.42e-05	0.000264	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—TP53—thyroid cancer	2.28e-05	0.000249	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—HRAS—thyroid cancer	2.18e-05	0.000238	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PTEN—thyroid cancer	2.11e-05	0.00023	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PTEN—thyroid cancer	2e-05	0.000218	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PPARG—thyroid cancer	1.97e-05	0.000215	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—AKT1—thyroid cancer	1.92e-05	0.00021	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—NRAS—thyroid cancer	1.78e-05	0.000195	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PTEN—thyroid cancer	1.67e-05	0.000183	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PTGS2—thyroid cancer	1.55e-05	0.000169	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—KRAS—thyroid cancer	1.53e-05	0.000167	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PTEN—thyroid cancer	1.35e-05	0.000148	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—HRAS—thyroid cancer	1.3e-05	0.000142	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—AKT1—thyroid cancer	1.21e-05	0.000133	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—AKT1—thyroid cancer	1.15e-05	0.000126	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—AKT1—thyroid cancer	9.64e-06	0.000105	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—AKT1—thyroid cancer	7.8e-06	8.51e-05	CbGpPWpGaD
